ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Scott Swanson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swanson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swanson, S.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2006;81:1042
© 2006 The Society of Thoracic Surgeons

Original article: General thoracic

Invited commentary

Scott Swanson, MD

Mt Sinai Medical Center, 1190 5th Ave, New York, NY 10029

(Email: scott.swanson{at}mountsinai.org).

The article by Mukhopadhyay and colleagues [1] investigates the mechanism for a potential new lung cancer treatment. Four nonsmall cell lung cancer lines and a normal lung fibroblast cell line were treated with Trichostatin A, a known anti-fungal agent and histone deacetylase inhibitor. The investigators find that there is a 10-fold difference in concentration necessary for cell death between the cancer cells and the normal cells, thus opening a potential therapeutic window for this drug. Furthermore they carefully investigate the mechanism for this effect suggesting that the gene p21 may play a pivotal role.

Clearly this work is early in its development and whether Trichostatin A becomes an effective treatment for human lung cancer is difficult to predict. With the advent of newer molecular biologic techniques, we can more easily investigate potential cancer pathways. Further studies to elucidate which genes are involved in the cell death witnessed with the use of Trichostatin A are now readily accomplished using microarray analysis. This development (ie, moving from observation to molecular mechanism) is easier and less labor intensive, and will accelerate major advances in cancer. Furthermore, and perhaps more importantly, such advances in molecular biology will permit surgeons to stay at the forefront of this critical research, for it is the surgical investigator who makes the observation that triggers the pertinent question, and it is the surgeon who has the most passionate interest of the patient in mind.


   References
Top
 References
 

  1. Mukhopadhyay NK, Weisberg E, Gilchrist D, Bueno R, Sugarbaker DJ, Jaklitsch MT, et al. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer Ann Thorac Surg 2006;81:1034-1042.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Scott Swanson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swanson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swanson, S.
Related Collections
Right arrow Lung - cancer

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS